Last reviewed · How we verify
XZP-3287+ Letrozole/Anastrozole
XZP-3287+ Letrozole/Anastrozole is a Aromatase inhibitor combination Small molecule drug developed by Xuanzhu Biopharmaceutical Co., Ltd.. It is currently in Phase 3 development for Hormone receptor-positive breast cancer (postmenopausal women).
XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.
XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer (postmenopausal women).
At a glance
| Generic name | XZP-3287+ Letrozole/Anastrozole |
|---|---|
| Sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
| Drug class | Aromatase inhibitor combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
XZP-3287 is combined with letrozole or anastrozole, which are aromatase inhibitors that reduce estrogen synthesis in postmenopausal women. The combination approach aims to enhance therapeutic efficacy in estrogen-dependent breast cancers by dual inhibition of estrogen signaling pathways. This strategy targets hormone receptor-positive breast cancer cells that depend on estrogen for growth.
Approved indications
- Hormone receptor-positive breast cancer (postmenopausal women)
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Vaginal dryness
- Bone loss/osteoporosis
Key clinical trials
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer (PHASE3)
- A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XZP-3287+ Letrozole/Anastrozole CI brief — competitive landscape report
- XZP-3287+ Letrozole/Anastrozole updates RSS · CI watch RSS
- Xuanzhu Biopharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about XZP-3287+ Letrozole/Anastrozole
What is XZP-3287+ Letrozole/Anastrozole?
How does XZP-3287+ Letrozole/Anastrozole work?
What is XZP-3287+ Letrozole/Anastrozole used for?
Who makes XZP-3287+ Letrozole/Anastrozole?
What drug class is XZP-3287+ Letrozole/Anastrozole in?
What development phase is XZP-3287+ Letrozole/Anastrozole in?
What are the side effects of XZP-3287+ Letrozole/Anastrozole?
Related
- Drug class: All Aromatase inhibitor combination drugs
- Manufacturer: Xuanzhu Biopharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive breast cancer (postmenopausal women)
- Compare: XZP-3287+ Letrozole/Anastrozole vs similar drugs
- Pricing: XZP-3287+ Letrozole/Anastrozole cost, discount & access